Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arrowhead Pharmaceuticals, Inc. (ARWR)
:ARWR
RESEARCH TOOLSreports
ARWR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$17.05 - $36.72
Previous CloseN/A
Volume680.40K
Average Volume (3M)2.27M
Market Cap
$2.58B
Enterprise Value$2.67B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.98
Next Earnings
May 08, 2025EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.15
Shares Outstanding126,098,114
10 Day Avg. Volume1,358,475
30 Day Avg. Volume2,269,969
Standard Deviation0.17
R-Squared0.09
Alpha-0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)426.02
Price to Cash Flow (P/CF)-4.40
P/FCF Ratio0.00
Enterprise Value/Market Cap1.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit751.83
Enterprise Value/Ebitda-4.60
Forecast
1Y Price Target
$40.40Price Target Upside91.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
---
Bulls Say, Bears Say
Bulls Say
Pipeline And InnovationArrowhead's targeted RNAi molecule (TRiM) platform enables delivery of small interfering RNA (siRNA) to the liver and to adipose tissue, representing important progress of RNAi therapeutics in obesity.
Regulatory MilestonesNDA filing places plozasiran on-track for potential approval for the treatment of familial chylomicronemia syndrome, which could generate near-term value for shareholders.
Strategic PartnershipsThe collaboration with SRPT has closed, and ARWR will receive $825mm, consisting of $500mm cash and $325mm as an equity investment priced at a 35% premium to 30-day volume weighted average price.
Bears Say
Financial And Business RisksRisks include clinical development risk, competitor risk, novel modality risk, commercialization risk, reimbursement risk, pricing risk, business development risk, capital market and dilution risk, and disruptions to clinical trials.
Funding RequirementsARWR continues to see rationale for a CVOT (CAPITAN trial in mixed dyslipidemia) but awaits substantial further capital to initiate the study.
Market CompetitionCompetitor risk could impact Arrowhead as other companies pursue similar novel treatments, potentially threatening market share.
---
Ownership Overview
4.52% Insiders
19.00% Mutual Funds
24.39% Other Institutional Investors
23.81% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ARWR FAQ
What was Arrowhead Pharmaceuticals, Inc.’s price range in the past 12 months?
Arrowhead Pharmaceuticals, Inc. lowest stock price was $17.05 and its highest was $36.72 in the past 12 months.
What is Arrowhead Pharmaceuticals, Inc.’s market cap?
Arrowhead Pharmaceuticals, Inc.’s market cap is $2.58B.
When is Arrowhead Pharmaceuticals, Inc.’s upcoming earnings report date?
Arrowhead Pharmaceuticals, Inc.’s upcoming earnings report date is May 08, 2025 which is in 76 days.
How were Arrowhead Pharmaceuticals, Inc.’s earnings last quarter?
Arrowhead Pharmaceuticals, Inc. released its earnings results on Feb 10, 2025. The company reported -$1.39 earnings per share for the quarter, missing the consensus estimate of -$0.405 by -$0.985.
Is Arrowhead Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Arrowhead Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Arrowhead Pharmaceuticals, Inc. pay dividends?
Arrowhead Pharmaceuticals, Inc. does not currently pay dividends.
What is Arrowhead Pharmaceuticals, Inc.’s EPS estimate?
Arrowhead Pharmaceuticals, Inc.’s EPS estimate is -0.11.
How many shares outstanding does Arrowhead Pharmaceuticals, Inc. have?
Arrowhead Pharmaceuticals, Inc. has 126,098,114 shares outstanding.
What happened to Arrowhead Pharmaceuticals, Inc.’s price movement after its last earnings report?
Arrowhead Pharmaceuticals, Inc. reported an EPS of -$1.39 in its last earnings report, missing expectations of -$0.405. Following the earnings report the stock price went down -5.171%.
Which hedge fund is a major shareholder of Arrowhead Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in ARWR
---
Arrowhead Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$40.40 (91.65% Upside)
$40.40 (91.65% Upside)
Blogger Sentiment
Bullish
ARWR Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 20.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $196.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 12.9%
Last 30 Days ▲ 12.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.49%
12-Months-Change
Fundamentals
Return on Equity
-600.68%
Trailing 12-Months
Asset Growth
61.86%
Trailing 12-Months
Company Description
Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
---
ARWR Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment with major highlights such as the closing of a significant deal with Sarepta Therapeutics, upcoming launches, and strong pipeline advancements in obesity and CNS. However, increased operating expenses and a higher net loss were noted as lowlights, with some uncertainties regarding the timing of the CVOT for plozasiran.Read More>---
ARWR Stock 12 Month Forecast
Average Price Target
$40.40
▲(91.65% Upside)
Technical Analysis
Alnylam Pharma
―
Ionis Pharmaceuticals
―
Sarepta Therapeutics
―
Arcturus Therapeutics
―
Moderna
―
Best Analysts Covering ARWR
1 Year
1 Year Success Rate
19/39 ratings generated profit
1 Year Average Return
+30.85%
reiterated a buy rating 10 days ago
Copying Keay Nakae's trades and holding each position for 1 Year would result in 48.72% of your transactions generating a profit, with an average return of +30.85% per trade.
---